
FDA Accepts sNDA for Sotyktu in PsA
Today, Bristol Myers Squibb announced the supplemental New Drug Application (sNDA) for deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) was accepted for review by the US FDA. The drug was assigned a Prescription …